Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Escitalopram
100%
Duloxetine
100%
Vortioxetine
100%
EEG Study
100%
Cortical Oscillations
100%
Quantitative Electroencephalography (qEEG)
100%
Multimodal Antidepressant
100%
Ondansetron
27%
Wakefulness
27%
SB-269970
27%
Occupancy
18%
5-HT3
18%
5-HT7
18%
5-HT1A Agonist
18%
Oscillation
9%
Positive Impact
9%
Cortical Function
9%
Receptor Antagonist
9%
EEG Recording
9%
Antagonism
9%
Cortical Activity
9%
5-hydroxytryptamine
9%
Cognitive Behavior
9%
5-HT Transporter
9%
5-HT1D Receptor
9%
Partial Agonist
9%
Transporter Inhibitor
9%
Target Occupancy
9%
In Vitro Autoradiography
9%
5-HT1A
9%
5-HT1B
9%
Awake Rat
9%
REM Sleep
9%
5-HT7 Antagonist
9%
Cortical Circuits
9%
5-HT3 Antagonist
9%
Quantitative Spectral Analysis
9%
Cognitive Metrics
9%
Neuronal Oscillations
9%
Clinical Impact
9%
Increased Power
9%
Agonism
9%
Neuroscience
Antidepressant
100%
Electroencephalography
100%
Vortioxetine
100%
Escitalopram
100%
Duloxetine
100%
Flesinoxan
45%
Wakefulness
27%
Serotonin
27%
Ondansetron
27%
5-HT1A Agonists
18%
Behavior (Neuroscience)
9%
Agonist
9%
Receptor Antagonist
9%
5-HT1D Receptor
9%
Autoradiograph
9%
5-HT3 Antagonist
9%
Pharmacology, Toxicology and Pharmaceutical Science
Escitalopram
100%
Antidepressant
100%
Duloxetine
100%
Vortioxetine
100%
Rat
100%
Flesinoxan
45%
Serotonin
27%
Zofran
27%
Serotonin 1A Agonist
18%
Clinical Study
9%
Partial Agonist
9%
Serotonin 1D Antagonist
9%
Autoradiography
9%
Serotonin 3 Antagonist
9%